The expanding role of anti-EGFR therapeutic modalities for the treatment of colorectal cancer patients, along with the growing number of cases potentially requiring such a treatment approach, made the need for a correct and reliable identification of responding tumours increasingly crucial. This evidence concerns the gene EGFR and colorectal cancer.